Prevention of rejection with BTI-322 after renal transplantation (Results at 9 months)

Transplantation Proceedings

Volumn 29, Issue 5, 1997, Pages 2425-2426

  Besse, T ^b   Malaise, J ^b   Mourad, M ^b   Pirson, Y ^b   Hope, J ^b   Awwad, M ^b   White Scharf, M ^b   Squifflet, J P ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BTI 322; CYCLOSPORIN A; IMMUNOGLOBULIN G2 ANTIBODY; IMMUNOSUPPRESSIVE AGENT; PREDNISOLONE; UNCLASSIFIED DRUG;

ADULT; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HUMAN CELL; HUMAN TISSUE; INFECTION RATE; KIDNEY TRANSPLANTATION; MALE; PRIORITY JOURNAL; SURVIVAL RATE;

ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD2; FEMALE; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED;

EID: 0030808473     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0041-1345(97)00432-6     Document Type: Conference Paper

References (2)

1. Latinne D, De La Parra B, Nizet Y, et al: Int Immunol 8:1113, 1996
2. Squifflet JP, Besse T, Malaise J, et al: Transplant Proc (in press), 1997